Company / Current Liabilities
ELITE PHARMACEUTICALS INC /NV/ Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$11.8M
FY2025
5-year range
$5.8M / $13.0M
FY2021-FY2025
Trend
-9.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has fluctuated over the past 10 years, ranging from $3M in FY2017 to $13M in FY2024.
Based on SEC 10-K filings.
$12M in FY2025 with a 5-year CAGR of +6.5%.
Increased from $8M to $12M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +20.9%
- 5-Year CAGR
- +6.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +6.5%, indicating consistent growth.
- In FY2025, current liabilities decreased 9.3% year-over-year.
- Peak current liabilities was recorded in FY2024.
- Lowest current liabilities in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.8M | -9.3% |
| FY2024 | $13.0M | +66.6% |
| FY2023 | $7.8M | +17.0% |
| FY2022 | $6.7M | +15.2% |
| FY2021 | $5.8M | -32.7% |
| FY2020 | $8.6M | +25.1% |
| FY2019 | $6.9M | +35.0% |
| FY2018 | $5.1M | +52.9% |
| FY2017 | $3.3M | -27.9% |
| FY2016 | $4.6M | -8.5% |
As of FY2025 · SEC 10-K · Updated Jun 29, 2026